Trials / Unknown
UnknownNCT04580498
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701+Paclitaxel+carboplatin | Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5 |
| DRUG | SHR-1701 | Drug: SHR-1701 30mg/kg |
Timeline
- Start date
- 2020-11-10
- Primary completion
- 2023-07-15
- Completion
- 2025-03-01
- First posted
- 2020-10-08
- Last updated
- 2023-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04580498. Inclusion in this directory is not an endorsement.